4:17 PM ET
8-K
Regulatory Approval
Quoin Pharmaceuticals Regulatory Approval
Quoin Pharmaceuticals announced that the FDA has granted Fast Track Designation to its lead asset, QRX003, for the treatment of Peeling Skin Syndrome. This is the first-ever Fast Track Designation granted for this rare genetic skin disease, which currently has no approved treatments. The company expects to initiate a Phase 2/3 clinical study for the indication in the second half of 2026.